|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | An alternative Kalman innovation filter approach for receiver position estimation based on GPS measurements显示文摘 | Jose I. Canelon Robert S. Provence Nisarg Mehta Leang S. Shieh | 2007 | International Journal of Systems Science2007，，12： | 1 |
| 2 | Tissue Engineering: Osteophilic Multilayer Coatings for Accelerated Bone Tissue Growth (Adv. Mater. 11/2012)显示文摘 | Nisarg J.Shah JinkeeHong Md. NasimHyder Paula T.Hammond | 2012 | Adv Mater2012，，11： | 1 |
| 3 | A comprehensive analysis of the role of molecular docking in the development of anticancer agents against the cell cycle CDK enzyme显示文摘Cancer is considered one of the most lethal diseases responsible for causing deaths worldwide.Although there have been many breakthroughs in anticancer development,cancer remains the major cause of death globally.In this regard,targeting cancer-causing enzymes is one of the efficient therapeutic strategies.Biological functions like cell cycle,transcription,metabolism,apoptosis,and other depend primarily on cyclin-dependent kinases(CDKs).These enzymes help in the replication of DNA in the normal cell cycle process,and deregulation in the functioning of any CDK can cause abnormal cell growth,which leads to cancer.This review is focused on anticancer drug discovery against cell cycle CDK enzyme using an in silico technique,i.e.,molecular docking studies.Molecular docking helps in deciphering the key interactions formed within the inhibitor and the respective enzyme.This concise study provides an overview of the most current in silico research advancements made in the field of anticancer drug discovery.The findings presented in the current review article can help in understanding the nature of inhibitor-target interactions and provide information on the structural and molecular prerequisites for the inhibition of cell cycle CDKs. | PRIYANKA SOLANKI NISARG RANA PRAKASH C.JHA ANU MANHAS | 2023 | BIOCELL2023，47，4： | 0 |
| 4 | Effectiveness of total therapy in immune thrombocytopenia purpura:case series显示文摘Immune Thrombocytopenic purpura(ITP)is a haematologicimmune-mediated disorder in which the amount of platelet in the blood decreases abnormally.Single-agent therapies for ITP have not proven successful in achieving long-term remission,with relapse occurring in about half of the patients(p/t).Treatment options which include Rituximab with Dexamethasone as frontline therapy,have durable response rates ranging from 58%to 76%.In this study,we have used‘Total therapy’as treatment which includes low-dose Rituximab in combination with Thrombopoietin receptor agonist(TPO-RA)(Romiplostim)and high-dose Dexamethasone.In this case series study,each patient received romiplostim(250 mcg weekly s/c,4 doses)in combination with low-dose rituximab(100 mg weekly IV,4 doses)and high-dose dexamethasone(40 mgIV on days 1-4and days 15-18).This treatment combination demonstrated rapid response rates and a low rate of side effects,making it a good alternative for individuals with ITP. | Nisarg R Hajariwala Hinal S Panchal Nira Amin Deeksha A Singh | 2022 | Cancer Advances2022，5，7： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员